APGE Stock Overview
Through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Apogee Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$43.46 |
| 52 Week High | US$72.29 |
| 52 Week Low | US$16.39 |
| Beta | 0 |
| 11 Month Change | -15.50% |
| 3 Month Change | -10.13% |
| 1 Year Change | 152.67% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 104.71% |
Recent News & Updates
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Nov 14
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Nov 10Recent updates
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Nov 14Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Nov 10We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Jun 20Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Jun 18We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow
Mar 05Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Mar 05We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn
Nov 21Shareholder Returns
| APGE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.0% | 2.4% | 2.2% |
| 1Y | 152.7% | 16.2% | 31.7% |
Return vs Industry: APGE exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: APGE exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| APGE volatility | |
|---|---|
| APGE Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APGE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: APGE's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 91 | Michael Henderson | www.apogeetherapeutics.com |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Apogee Therapeutics, Inc. Fundamentals Summary
| APGE fundamental statistics | |
|---|---|
| Market cap | US$2.44b |
| Earnings (TTM) | -US$146.66m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-16.9x
P/E RatioIs APGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APGE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$146.66m |
| Earnings | -US$146.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did APGE perform over the long term?
See historical performance and comparison